The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells

Lehmann,Tomasz  P.; Wrzesiński,Tomasz; Jagodziński,Paweł  P.

doi:10.3892/mmr.2012.1244

The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells

Authors:
- Tomasz P. Lehmann
- Tomasz Wrzesiński
- Paweł P. Jagodziński
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan 60‑781, Poland
Published online on: December 18, 2012 https://doi.org/10.3892/mmr.2012.1244
Pages: 893-900

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitotane, also known as o,p'‑DDD or (RS)‑1‑chloro‑2‑[2,2‑dichloro‑1‑(4‑chlorophenyl)‑ethyl]‑benzene, is an adrenal cortex-specific cytotoxic drug used in the therapy of adrenocortical carcinoma (ACC). The drug also inhibits steroidogenesis, however, the mechanisms of its anticancer and antisteroidogenic effects remain unknown. At present, data on the impact of mitotane on cell viability and the regulation of genes encoding proteins associated with steroids synthesis in the adrenal cortex, including cortisol and dehydroepiandrosterone sulfate (DHEAS), are limited and contradictory. In the present study, the effect of 24‑h mitotane treatment on viability of the ACC cell line, NCI‑H295R, was analyzed, identifying a decrease in cell viability and an increase in caspase‑3 and ‑7 activities. Mitotane treatment also led to decreased cortisol and DHEAS concentration in the culture media. Concomitantly, mitotane resulted in decreased mRNA levels of two cytochromes P450 (CYP11A1 and CYP17A1), mRNAs encoding proteins involved in the synthesis of cortisol and DHEAS. Mitotane did not affect mRNA levels of cyclin dependent kinase inhibitor 1A (encoding p21) and MYC (encoding cMyc). cMyc and p21 are key transcription factors associated with cell cycle regulation. However, mitotane inhibited expression of transforming growth factor β1 gene, encoding a potent inhibitor of cell proliferation and steroidogenesis. PRKAR1A, a protein kinase A regulatory subunit, is involved in the activation of steroidogenesis. PRKAR1A mRNA levels were reduced following 24‑h treatment with mitotane. Results indicate that mitotane markedly inhibited expression of genes involved in steroidogenesis, secretion of cortisol and DHEAS. Reduced expression of TGFB1 cannot account fully for the effect of mitotane on CYP11A1 and CYP17A1. We hypothesized that reduced viability of NCI‑H295R cells in the presence of mitotane may be a result of apoptosis triggered by increased caspase‑3 and ‑7 activities. Since p21 and cMyc mRNA levels were stable in the presence of mitotane, the mechanism by which caspase‑3 and ‑7 are induced remains unknown.

View Figures

View References

1	Hahner S and Fassnacht M: Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 6:386–394. 2005.PubMed/NCBI
2	Huang H and Fojo T: Adjuvant mitotane for adrenocortical cancer - a recurring controversy. J Clin Endocrinol Metab. 93:3730–3732. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR and Baudin E: Plasma concentrations of o,p'DDD, o,p'DDA and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 96:1844–1851. 2011.
4	Allolio B and Fassnacht M: Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 91:2027–2037. 2006. View Article : Google Scholar : PubMed/NCBI
5	Libe R, Fratticci A and Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 14:13–28. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kirschner LS: Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab. 91:14–21. 2006. View Article : Google Scholar : PubMed/NCBI
7	Zini L, Porpiglia F and Fassnacht M: Contemporary management of adrenocortical carcinoma. Eur Urol. 60:1055–1065. 2011. View Article : Google Scholar : PubMed/NCBI
8	Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ and Krans HM: Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 69:947–951. 1994. View Article : Google Scholar : PubMed/NCBI
9	Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP and Le Bouc Y: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 61:6762–6767. 2001.PubMed/NCBI
10	Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reynies A and Bertherat J: Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 70:8276–8281. 2010.
11	Asp V, Ulleras E, Lindstrom V, Bergstrom U, Oskarsson A and Brandt I: Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. Toxicol Appl Pharmacol. 242:281–289. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lin CW, Chang YH and Pu HF: Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicology. 298:14–23. 2012. View Article : Google Scholar : PubMed/NCBI
13	Gilep AA, Sushko TA and Usanov SA: At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochim Biophys Acta. 1814:200–209. 2011. View Article : Google Scholar : PubMed/NCBI
14	Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE and Miller WL: Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci USA. 84:407–411. 1987. View Article : Google Scholar : PubMed/NCBI
15	Miller WL: Minireview: regulation of steroidogenesis by electron transfer. Endocrinology. 146:2544–2550. 2005. View Article : Google Scholar : PubMed/NCBI
16	Staels B, Hum DW and Miller WL: Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. Mol Endocrinol. 7:423–433. 1993.PubMed/NCBI
17	Ahlman H, Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Jacobsson CE and Lindstedt S: Cytotoxic treatment of adrenocortical carcinoma. World J Surg. 25:927–933. 2001. View Article : Google Scholar : PubMed/NCBI
18	Pushkarev VM, Tronko ND, Kostyuchenko NN and Mikosha AS: Effect of o,p'-DDD and Li⁺ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex. Ukr Biokhim Zh. 79:44–49. 2007.
19	de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O and Feige JJ: Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 90:1819–1829. 2005.
20	Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S and Lichter P: Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer. 28:145–152. 2000. View Article : Google Scholar : PubMed/NCBI
21	Kjellman M, Kallioniemi OP, Karhu R, Hoog A, Farnebo LO, Auer G, Larsson C and Backdahl M: Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 56:4219–4223. 1996.
22	Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM and Demeure MJ: Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther. 7:425–431. 2008. View Article : Google Scholar : PubMed/NCBI
23	Moore CC, Hum DW and Miller WL: Identification of positive and negative placenta-specific basal elements and a cyclic adenosine 3′,5′-monophosphate response element in the human gene for P450scc. Mol Endocrinol. 6:2045–2058. 1992.PubMed/NCBI
24	Sewer MB, Nguyen VQ, Huang CJ, Tucker PW, Kagawa N and Waterman MR: Transcriptional activation of human CYP17 in H295R adrenocortical cells depends on complex formation among p54(nrb)/NonO, protein-associated splicing factor and SF-1, a complex that also participates in repression of transcription. Endocrinology. 143:1280–1290. 2002. View Article : Google Scholar
25	Asp V, Lindstrom V, Olsson JA, Bergstrom U and Brandt I: Cytotoxicity and decreased corticosterone production in adrenocortical Y-1 cells by 3-methylsulfonyl-DDE and structurally related molecules. Arch Toxicol. 83:389–396. 2009. View Article : Google Scholar : PubMed/NCBI
26	Shi YQ, Li HW, Wang YP, Liu CJ and Yang KD: p,p'-DDE induces apoptosis and mRNA expression of apoptosis-associated genes in testes of pubertal rats. Environ Toxicol. Mar 7–2011.(Epub ahead of print).
27	Burow ME, Tang Y, Collins-Burow BM, Krajewski S, Reed JC, McLachlan JA and Beckman BS: Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells. Carcinogenesis. 20:2057–2061. 1999. View Article : Google Scholar : PubMed/NCBI
28	Boatright KM and Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol. 15:725–731. 2003. View Article : Google Scholar : PubMed/NCBI
29	Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, Inayat I and Flavell RA: Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science. 311:847–851. 2006. View Article : Google Scholar : PubMed/NCBI
30	Alenzi FQ, Lotfy M and Wyse R: Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev. 11:271–280. 2010.PubMed/NCBI
31	Fuentes-Prior P and Salvesen GS: The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 384:201–232. 2004. View Article : Google Scholar : PubMed/NCBI
32	Hogel H, Rantanen K, Jokilehto T, Grenman R and Jaakkola PM: Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One. 6:e271122011. View Article : Google Scholar : PubMed/NCBI
33	Wilhelm S, Wagner H and Hacker G: Activation of caspase-3-like enzymes in non-apoptotic T cells. Eur J Immunol. 28:891–900. 1998. View Article : Google Scholar : PubMed/NCBI
34	Feige JJ, Cochet C and Chambaz EM: Type beta transforming growth factor is a potent modulator of differentiated adrenocortical cell functions. Biochem Biophys Res Commun. 139:693–700. 1986. View Article : Google Scholar : PubMed/NCBI
35	Riopel L, Branchaud CL, Goodyer CG, Adkar V and Lefebvre Y: Growth-inhibitory effect of TGF-B on human fetal adrenal cells in primary monolayer culture. J Cell Physiol. 140:233–238. 1989. View Article : Google Scholar : PubMed/NCBI
36	Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, Fierrard H, Perlemoine K, Martinez A and Bertherat J: Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res. 69:7278–7284. 2009. View Article : Google Scholar : PubMed/NCBI
37	Khaidakov M, Szwedo J, Mitra S and Mehta JL: Angiostatic effects of aspirin in hypoxia-reoxygenation are linked to modulation of TGFbeta1 signaling. J Cardiovasc Pharmacol Ther. 16:105–110. 2011. View Article : Google Scholar : PubMed/NCBI
38	Nieminen AI, Partanen JI and Klefstrom J: c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle. 6:2464–2472. 2007. View Article : Google Scholar : PubMed/NCBI
39	Prendergast GC: Mechanisms of apoptosis by c-Myc. Oncogene. 18:2967–2987. 1999. View Article : Google Scholar : PubMed/NCBI
40	Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 1:639–649. 2002.PubMed/NCBI
41	Shin H, Lee YS and Lee YC: Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Oncol Rep. 27:1111–1115. 2012.PubMed/NCBI
42	Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y and Akahane K: Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ. 7:721–728. 2000. View Article : Google Scholar : PubMed/NCBI
43	Tait SW and Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 11:621–632. 2011. View Article : Google Scholar : PubMed/NCBI
44	Chen CW, Hurd C, Vorojeikina DP, Arnold SF and Notides AC: Transcriptional activation of the human estrogen receptor by DDT isomers and metabolites in yeast and MCF-7 cells. Biochem Pharmacol. 53:1161–1172. 1997. View Article : Google Scholar : PubMed/NCBI
45	Gell JS, Oh J, Rainey WE and Carr BR: Effect of estradiol on DHEAS production in the human adrenocortical cell line, H295R. J Soc Gynecol Investig. 5:144–148. 1998. View Article : Google Scholar : PubMed/NCBI
46	Vanttinen T, Liu J, Kuulasmaa T, Kivinen P and Voutilainen R: Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. J Endocrinol. 178:479–489. 2003. View Article : Google Scholar : PubMed/NCBI